Abstract:Study M05-730 was conducted to compare the safety, tolerability, pharmacokinetics (PK) and antiviral activity for once-daily (QD) and twice-daily (BID) lopinavir/ritonavir (LPV/r) tablet in antiretroviral-naïve subjects. The LPV/ r QD regimen was shown to be non-inferior to the BID regimen. This analysis explores the population PK and pharmacodynamics (PD) of the LPV/r tablets in HIVinfected subjects.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.